OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Abstract
MicroRNAs (miRNAs) belong to a recently discovered class of small RNA molecules that regulate gene expression at the post-transcriptional level. miRNAs have crucial functions in the development and establishment of cell identity, and aberrant metabolism or expression of miRNAs has been linked to human diseases, including cancer. Components of the miRNA machinery and miRNAs themselves are involved in many cellular processes that are altered in cancer, such as differentiation, proliferation and apoptosis. Some miRNAs, referred to as oncomiRs, show differential expression levels in cancer and are able to affect cellular transformation, carcinogenesis and metastasis, acting either as oncogenes or tumour suppressors. The phenomenon of 'oncogene addiction' reveals that despite the multistep nature of tumorigenesis, targeting of certain single oncogenes can have therapeutic value, and the possibility of oncomiR addiction has been proposed but never demonstrated. MicroRNA-21 (miR-21) is a unique miRNA in that it is overexpressed in most tumour types analysed so far. Despite great interest in miR-21, most of the data implicating it in cancer have been obtained through miRNA profiling and limited in vitro functional assays. To explore the role of miR-21 in cancer in vivo, we used Cre and Tet-off technologies to generate mice conditionally expressing miR-21. Here we show that overexpression of miR-21 leads to a pre-B malignant lymphoid-like phenotype, demonstrating that mir-21 is a genuine oncogene. When miR-21 was inactivated, the tumours regressed completely in a few days, partly as a result of apoptosis. These results demonstrate that tumours can become addicted to oncomiRs and support efforts to treat human cancers through pharmacological inactivation of miRNAs such as miR-21.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works
Oncomirs — microRNAs with a role in cancer
Esquela‐Kerscher, A., & Slack, F. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1840 · Cited by 7,038 · see citing works
Self-citationA microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697 · see citing works
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053 · see citing works
Koopman, G., Reutelingsperger, C. P. M., Kuijten, G., Keehnen, R. M. J., Pals, S. T., & van Oers, M. H. J. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,687 · see citing works
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557 · see citing works
Koopman, G., Reutelingsperger, C., Kuijten, G., et al. (1994) · Blood · doi:10.1182/blood.v84.5.1415.bloodjournal8451415 · Cited by 2,068 · see citing works
Si, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600 · see citing works
Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, N., Yuen, S. T., Chan, T. L., Kwong, D. L. �., Au, G. K. �., et al. (2008) · JAMA · doi:10.1001/jama.299.4.425 · Cited by 1,578 · see citing works
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051 · see citing works
Reversible tumorigenesis by MYC in hematopoietic lineages.
Felsher, D., & Bishop, J. (1999) · Molecules and Cells · doi:10.1016/s1097-2765(00)80367-6 · Cited by 917 · see citing works
Zambrowicz, B., Imamoto, A., Fiering, S., Herzenberg, L. A., Kerr, W. G., & Soriano, P. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3789 · Cited by 850 · see citing works
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Shuomin, Zhu, Hailong, H., Wu, Fangting, Daotai, Nie, Shijie, Sheng, Yin-Yuan, et al. (2008) · Cell Research · Cited by 831 · see citing works
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805 · see citing works
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 708 · see citing works
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500 · see citing works
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia
Fulci, V., Chiaretti, S., Goldoni, M., Azzalin, G., Carucci, N., Tavolaro, S., Castellano, L., Magrelli, A., Citarella, F., Messina, M., et al. (2007) · Blood · doi:10.1182/blood-2006-12-062398 · Cited by 498 · see citing works
Oncogene addiction: setting the stage for molecularly targeted cancer therapyPreprint
Sharma, S. V., & Settleman, J. E. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 442 · see citing works
MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor
Li, J., Huang, H., Sun, L., Yang, M., Pan, C., Chen, W., Wu, D., Lin, Z., Zeng, C., Yao, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3053 · Cited by 434 · see citing works
Reversibility of acute B-cell leukaemia induced by BCR–ABL1
Huettner, C. S., Zhang, P., Etten, R. A. V., & Tenen, D. G. (2000) · Nature Genetics · doi:10.1038/71691 · Cited by 413 · see citing works
Lawrie, C. H., Soneji, S., Marafioti, T., Cooper, C. D. O., Palazzo, S., Paterson, J. C., Cattan, H., Enver, T., Mager, R., Boultwood, J., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22800 · Cited by 410 · see citing works
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
Jongen‐Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. M., & Löwenberg, B. (2008) · Blood · doi:10.1182/blood-2008-01-133355 · Cited by 401 · see citing works
Li, T., Li, D., Sha, J., Sun, P., & Huang, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.077 · Cited by 370 · see citing works
Bethesda proposals for classification of lymphoid neoplasms in mice
Morse, H. C. (2002) · Blood · doi:10.1182/blood.v100.1.246 · Cited by 345 · see citing works
MicroRNAs and cancer: An overview
Medina, P. P., & Slack, F. J. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6453 · Cited by 340 · see citing works
Self-citationProgenitor cell maintenance requires numb and numblike during mouse neurogenesis
Petersen, P. H., Zou, K., Hwang, J. K., Jan, Y. N., & Zhong, W. (2002) · Nature · doi:10.1038/nature01124 · Cited by 330 · see citing works
Costinean, S., Sandhu, S. K., Pedersen, I. M., Tili, E., Trotta, R., Perrotti, D., Ciarlariello, D., Neviani, P., Harb, J. G., Kauffman, L. R., et al. (2009) · Blood · doi:10.1182/blood-2009-05-220814 · Cited by 292 · see citing works
MicroRNA expression profiling in classic Hodgkin lymphoma
Navarro, A., Gayà, A., Martı́nez, A., Urbano-Ispizúa, Á., Pons, A., Balagué, O., Gel, B., Abrisqueta, P., López‐Guillermo, A., Artells, R., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096784 · Cited by 170 · see citing works
Transcriptional control of the endogenous MYC protooncogene by antisense RNA.
Yokoyama, K., & Imamoto, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7363 · Cited by 150 · see citing works
An ES cell system for rapid, spatial and temporal analysis of gene function in vitro and in vivo
Mao, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni146 · Cited by 50 · see citing works
High frequency of normal DJH joints in B cell progenitors in severe combined immunodeficiency mice.
Pennycook, J. L. M. H., Chang, Y., Celler, J. W., Phillips, R. A., & Wu, G. E. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.3.1007 · Cited by 32 · see citing works
Imai, Y., Adachi, Y., Shi, M., Shima, C., Yanai, S., Okigaki, M., Yamashima, T., Kaneko, K., & Ikehara, S. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0251 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · see citing works
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619 · see citing works
Self-citationLujambio, A., & Lowe, S. W. (2012) · Nature · doi:10.1038/nature10888 · Cited by 1,084 · see citing works
Tian, T., Zhu, Y.-L., Zhou, Y.-Y., Liang, G.-F., Wang, Y.-Y., Hu, F.-H., & Xiao, Z.-D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.588046 · Cited by 726 · see citing works
MicroRNAs as regulatory elements in immune system logic
Mehta, A., & Baltimore, D. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.40 · Cited by 704 · see citing works
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431 · see citing works
“miR-21, another bona fide human oncogene (Medina et al., 2010), and miR-27a, also are also generally positively correlating with MYC expression.”
Noncoding <scp>RNA</scp>s in disease
Lekka, E., & Hall, J. (2018) · FEBS Letters · doi:10.1002/1873-3468.13182 · Cited by 251 · see citing works
Perdiguero, E., Sousa-Victor, P., Ruiz-Bonilla, V., Jardí, M., Caelles, C., Serrano, A. L., & Muñoz-Cánoves, P. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201104053 · Cited by 236 · see citing works
Liu, Y., Li, Y., Li, N., Teng, W., Wang, M., Zhang, Y., & Xiao, Z. (2016) · Scientific Reports · doi:10.1038/srep32231 · Cited by 179 · see citing works
Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions
Matsuhashi, S., Manirujjaman, M., Hamajima, H., & Ozaki, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092304 · Cited by 143 · see citing works
Inhibition of miR-21 in glioma cells using catalytic nucleic acids
Belter, A., Rolle, K., Piwecka, M., Fedoruk-Wyszomirska, A., Naskręt-Barciszewska, M. Z., & Barciszewski, J. (2016) · Scientific Reports · doi:10.1038/srep24516 · Cited by 36 · see citing works
Yu, Y., Yao, Y., Yan, H., Wang, R., Zhang, Z., Sun, X., Zhao, L., Ao, X., Xie, Z., & Wu, Q. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.28 · Cited by 31 · see citing works
- Authors
- Medina, P. P., Nolde, M., & Slack, F. J.
- Affiliations
- Yale University (US)
- Corresponding author
- Slack, Frank J.
- Venue
- Nature
- Published
- 2010-08-08
- Volume
- 467
- Issue
- 7311
- Pages
- 86-90
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2067915426
- Semantic Scholar
- cf348a0cefe0fedd7d15bf8a2b58725dbcaf5c30
- Cited by
- 971
- References
- 32
- Citations by year
- 2026: 24 · 2025: 26 · 2024: 31 · 2023: 30 · 2022: 43 · 2021: 47 · 2020: 47 · 2019: 63 · 2018: 55 · 2017: 68 · 2016: 67 · 2015: 88 · 2014: 89 · 2013: 94 · 2012: 104
- FWCI
- 26.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-21, pre-B cell lymphoma, oncogene addiction, apoptosis, tumor regression, post-transcriptional regulation, miRNA-based therapy
- MeSH terms
- Animals, Mice, Inbred C57BL, Mice, Transgenic, Lymphoma, B-Cell, MicroRNAs, Mice, Precursor Cells, B-Lymphoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
